Clinical TrialIRONNCT05329129

OssDsign® Spine Registry Study ("Propel") FDA Decision: Disc Medicine (IRON)

Decision Date
March 23, 2027
292 days away

Drug Overview

Drug / TherapyOssDsign® Spine Registry Study ("Propel")
Indication—
Decision TypeClinical Trial
Trial PhaseClinical Trial
ClinicalTrials.govNCT05329129

Company Overview

Disc Medicine (IRON) operates in the Hematology sector. The current BTS Score is 52 (Grade: C).

Dilution Risk Assessment

Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.

Frequently Asked Questions

Q:When is the Clinical Trial date for OssDsign® Spine Registry Study ("Propel")?

The Clinical Trial date for OssDsign® Spine Registry Study ("Propel") by Disc Medicine (IRON) is scheduled for March 23, 2027. This is the target date for the FDA to make a decision on this application.

Q:What is OssDsign® Spine Registry Study ("Propel") used for?

OssDsign® Spine Registry Study ("Propel") is being developed by Disc Medicine for the treatment of its target indication. It is currently in Clinical Trial clinical trials.

Q:What happens if OssDsign® Spine Registry Study ("Propel") gets FDA approval?

If OssDsign® Spine Registry Study ("Propel") receives FDA approval, Disc Medicine (IRON) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Clinical Trial date closely.

Q:What is the dilution risk for IRON?

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IRON on DilutionWatch at dilutionwatch.com/stock/IRON.html.

Q:Where can I find more information about Disc Medicine?

You can view the full BiotechSigns company profile for Disc Medicine (IRON) at biotechsign.com/app/company/IRON, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.

Disclaimer

This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.